Phase II trial of vinblastine in previously treated patients with ovarian cancer: A Southwest Oncology Group study

E. A. Surwit; D. S. Alberts; R. V. O'Toole; V. Graham; E. V. Hannigan; R. L. Stephens; J. G. Boutselis

doi:10.1016/0090-8258(87)90295-2

Phase II trial of vinblastine in previously treated patients with ovarian cancer: A Southwest Oncology Group study

E. A. Surwit, D. S. Alberts, R. V. O'Toole, V. Graham, E. V. Hannigan, R. L. Stephens, J. G. Boutselis

Cancer Center

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Sixty-eight patients with relapsing, epithelial type ovarian carcinoma were entered into a Phase II study of vinblastine. Vinblastine was administered as a continuous intravenous infusion over five days at a starting dose of 1.7 mg/m²/day every 3 weeks. There were 44 fully evaluable and 6 partially evaluable patients. Forty-one of these patients had had only one prior treatment regimen. Grade 3 or 4 leukopenia occurred in 12 patients (24%), but Grade 3 or 4 thrombocytopenia occurred in only 2 patients. There were two clinical complete responses of 18 and 36 weeks duration and one partial response of 6 weeks for an overall response rate of 7%. We conclude that vinblastine, administered in optimal dose and schedule, has little clinical activity in previously treated patients with ovarian cancer.

Original language	English (US)
Pages (from-to)	214-219
Number of pages	6
Journal	Gynecologic oncology
Volume	27
Issue number	2
DOIs	https://doi.org/10.1016/0090-8258(87)90295-2
State	Published - Jun 1987

ASJC Scopus subject areas

Oncology
Obstetrics and Gynecology

Access to Document

10.1016/0090-8258(87)90295-2

Fingerprint Dive into the research topics of 'Phase II trial of vinblastine in previously treated patients with ovarian cancer: A Southwest Oncology Group study'. Together they form a unique fingerprint.

Cite this

@article{fe4ae7cf4a7342548a599a83d1f83c82,

title = "Phase II trial of vinblastine in previously treated patients with ovarian cancer: A Southwest Oncology Group study",

abstract = "Sixty-eight patients with relapsing, epithelial type ovarian carcinoma were entered into a Phase II study of vinblastine. Vinblastine was administered as a continuous intravenous infusion over five days at a starting dose of 1.7 mg/m2/day every 3 weeks. There were 44 fully evaluable and 6 partially evaluable patients. Forty-one of these patients had had only one prior treatment regimen. Grade 3 or 4 leukopenia occurred in 12 patients (24%), but Grade 3 or 4 thrombocytopenia occurred in only 2 patients. There were two clinical complete responses of 18 and 36 weeks duration and one partial response of 6 weeks for an overall response rate of 7%. We conclude that vinblastine, administered in optimal dose and schedule, has little clinical activity in previously treated patients with ovarian cancer.",

author = "Surwit, {E. A.} and Alberts, {D. S.} and O'Toole, {R. V.} and V. Graham and Hannigan, {E. V.} and Stephens, {R. L.} and Boutselis, {J. G.}",

year = "1987",

month = jun,

doi = "10.1016/0090-8258(87)90295-2",

language = "English (US)",

volume = "27",

pages = "214--219",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

number = "2",

}

TY - JOUR

T1 - Phase II trial of vinblastine in previously treated patients with ovarian cancer

T2 - A Southwest Oncology Group study

AU - Surwit, E. A.

AU - Alberts, D. S.

AU - O'Toole, R. V.

AU - Graham, V.

AU - Hannigan, E. V.

AU - Stephens, R. L.

AU - Boutselis, J. G.

PY - 1987/6

Y1 - 1987/6

N2 - Sixty-eight patients with relapsing, epithelial type ovarian carcinoma were entered into a Phase II study of vinblastine. Vinblastine was administered as a continuous intravenous infusion over five days at a starting dose of 1.7 mg/m2/day every 3 weeks. There were 44 fully evaluable and 6 partially evaluable patients. Forty-one of these patients had had only one prior treatment regimen. Grade 3 or 4 leukopenia occurred in 12 patients (24%), but Grade 3 or 4 thrombocytopenia occurred in only 2 patients. There were two clinical complete responses of 18 and 36 weeks duration and one partial response of 6 weeks for an overall response rate of 7%. We conclude that vinblastine, administered in optimal dose and schedule, has little clinical activity in previously treated patients with ovarian cancer.

AB - Sixty-eight patients with relapsing, epithelial type ovarian carcinoma were entered into a Phase II study of vinblastine. Vinblastine was administered as a continuous intravenous infusion over five days at a starting dose of 1.7 mg/m2/day every 3 weeks. There were 44 fully evaluable and 6 partially evaluable patients. Forty-one of these patients had had only one prior treatment regimen. Grade 3 or 4 leukopenia occurred in 12 patients (24%), but Grade 3 or 4 thrombocytopenia occurred in only 2 patients. There were two clinical complete responses of 18 and 36 weeks duration and one partial response of 6 weeks for an overall response rate of 7%. We conclude that vinblastine, administered in optimal dose and schedule, has little clinical activity in previously treated patients with ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=0023258160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023258160&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(87)90295-2

DO - 10.1016/0090-8258(87)90295-2

M3 - Article

C2 - 3570059

AN - SCOPUS:0023258160

VL - 27

SP - 214

EP - 219

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -